| Attribute |
Value |
| 52 Week Change |
-0.43555558 |
| Address1 |
5,959 Horton Street |
| Address2 |
7th Floor |
| All Time High |
12.74 |
| All Time Low |
1.13 |
| Ask |
1.62 |
| Ask Size |
2 |
| Average Analyst Rating |
1.5 - Strong Buy |
| Average Daily Volume10 Day |
225,580 |
| Average Daily Volume3 Month |
179,126 |
| Average Volume |
179,126 |
| Average Volume10Days |
225,580 |
| Beta |
0.698 |
| Bid |
0.9504 |
| Bid Size |
2 |
| Book Value |
3.66 |
| City |
EmeryVille |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
1.32 |
| Current Ratio |
6.425 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
1.33 |
| Day Low |
1.26 |
| Debt To Equity |
28.44 |
| Display Name |
Metagenomi Therapeutics |
| Earnings Timestamp End |
1,755,115,200 |
| Earnings Timestamp Start |
1,755,115,200 |
| Ebitda |
-87,546,000 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
0.586 |
| Enterprise To Revenue |
-2.296 |
| Enterprise Value |
-51,282,148 |
| Eps Current Year |
-2.225 |
| Eps Forward |
-2.29 |
| Eps Trailing Twelve Months |
-2.29 |
| Esg Populated |
0 |
| Exchange |
NMS |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
1.2934 |
| Fifty Day Average Change |
0.026600003 |
| Fifty Day Average Change Percent |
0.020565951 |
| Fifty Two Week Change Percent |
-43.555557 |
| Fifty Two Week High |
3.95 |
| Fifty Two Week High Change |
-2.63 |
| Fifty Two Week High Change Percent |
-0.6658228 |
| Fifty Two Week Low |
1.13 |
| Fifty Two Week Low Change |
0.19000006 |
| Fifty Two Week Low Change Percent |
0.16814165 |
| Fifty Two Week Range |
1.13 - 3.95 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,707,489,000,000 |
| Float Shares |
25,437,982 |
| Forward Eps |
-2.29 |
| Forward P E |
-0.57641923 |
| Free Cashflow |
-56,654,500 |
| Full Exchange Name |
NasdaqGS |
| Full Time Employees |
118 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.0 |
| Gross Profits |
-71,685,000 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.18965 |
| Held Percent Institutions |
0.19511999 |
| Implied Shares Outstanding |
37,646,858 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Ipo Expected Date |
2,024-02-09 |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Long Business Summary |
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California. |
| Long Name |
Metagenomi Therapeutics, Inc. |
| Market |
us_market |
| Market Cap |
49,693,852 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_633445224 |
| Most Recent Quarter |
1,774,915,200 |
| Name Change Date |
2,026-07-13 |
| Net Income To Common |
-85,888,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
49,618,558 |
| Number Of Analyst Opinions |
2 |
| Open |
1.29 |
| Operating Cashflow |
-87,225,000 |
| Operating Margins |
-19.70112 |
| Payout Ratio |
0.0 |
| Phone |
510 871 4880 |
| Prev Name |
Metagenomi, Inc. |
| Previous Close |
1.27 |
| Price Eps Current Year |
-0.5932585 |
| Price Hint |
4 |
| Price To Book |
0.36065575 |
| Price To Sales Trailing12 Months |
2.2253304 |
| Profit Margins |
0.0 |
| Quick Ratio |
6.274 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
strong_buy |
| Recommendation Mean |
1.5 |
| Region |
US |
| Regular Market Change |
0.0500001 |
| Regular Market Change Percent |
3.93701 |
| Regular Market Day High |
1.33 |
| Regular Market Day Low |
1.26 |
| Regular Market Day Range |
1.26 - 1.33 |
| Regular Market Open |
1.29 |
| Regular Market Previous Close |
1.27 |
| Regular Market Price |
1.32 |
| Regular Market Time |
1,783,972,801 |
| Regular Market Volume |
372,375 |
| Return On Assets |
-0.23437999 |
| Return On Equity |
-0.49016997 |
| Revenue Growth |
-0.698 |
| Revenue Per Share |
0.597 |
| Sand P52 Week Change |
0.20847368 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
37,646,858 |
| Shares Percent Shares Out |
0.044699997 |
| Shares Short |
1,684,034 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
1,831,424 |
| Short Name |
Metagenomi Therapeutics, Inc. |
| Short Percent Of Float |
0.0552 |
| Short Ratio |
11.21 |
| Source Interval |
15 |
| State |
CA |
| Symbol |
MGX |
| Target High Price |
9.0 |
| Target Low Price |
5.0 |
| Target Mean Price |
7.0 |
| Target Median Price |
7.0 |
| Total Cash |
140,162,000 |
| Total Cash Per Share |
3.723 |
| Total Debt |
39,186,000 |
| Total Revenue |
22,331,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-2.29 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
1.693 |
| Two Hundred Day Average Change |
-0.3729999 |
| Two Hundred Day Average Change Percent |
-0.22031891 |
| Type Disp |
Equity |
| Volume |
372,375 |
| Website |
https://metagenomi.co |
| Zip |
94,608 |